Forte Biosciences Dividendo

Dividendo criteri di controllo 0/6

Forte Biosciences does not have a record of paying a dividend.

Informazioni chiave

n/a

Rendimento del dividendo

-404.4%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-404.4%
Rendimento futuro dei dividendi	n/a
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Jul 17

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Dec 23

Forte Biosciences files for $300M mixed shelf offering

May 28

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Mar 13

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Jan 19

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Nov 25

Forte Biosciences readies equity offering

Oct 28

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Insufficient data to determine if FBRX's dividends per share have been stable in the past.

Dividendo in crescita: Insufficient data to determine if FBRX's dividend payments have been increasing.

Rendimento dei dividendi rispetto al mercato

Forte Biosciences Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di FBRX rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (FBRX)	n/a
Fondo del 25% del mercato (US)	1.5%
Top 25% del mercato (US)	4.5%
Media del settore (Biotechs)	2.2%
Analista previsionale (FBRX) (fino a 3 anni)	n/a

Dividendo notevole: Unable to evaluate FBRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividendo elevato: Unable to evaluate FBRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Distribuzione degli utili agli azionisti

Copertura degli utili: Insufficient data to calculate FBRX's payout ratio to determine if its dividend payments are covered by earnings.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Unable to calculate sustainability of dividends as FBRX has not reported any payouts.

Forte Biosciences Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

High number of new directors

High number of new directors

New major risk - Market cap size

New major risk - Share price stability

Price target increased by 25% to US$4.38

Forte Biosciences, Inc., Annual General Meeting, Aug 20, 2024

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

New minor risk - Share price stability

New major risk - Financial position

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

New major risk - Financial position

High number of new directors

Forte Biosciences Receives Non-Compliance Letter from Nasdaq

Camac Partners Shares Key Facts that Reinforce the Need for Urgent Change in Forte Biosciences’s Boardroom

Forte Biosciences, Inc., Annual General Meeting, Sep 19, 2023

New major risk - Shareholder dilution

Forte Biosciences, Inc appoints David Gryska to the Board of Directors

CEO & Chairman recently bought US$105k worth of stock

High number of new and inexperienced directors

Forte Biosciences, Inc. Announces Dr. Scott Brun to Its Board of Directors

Cable Car Capital Expects Response of Forte Biosciences for its Concerns

Cable Car Capital Waiting for the Response of Forte Biosciences

Cable Car Capital Sends Letter to the Board of Forte Biosciences

Large Forte Biosciences shareholder scolds company board of directors

Camac Partners, LLC Urges the Board to Reverse Course and Return Capital to Shareholders

Camac Partners, LLC Urges the Board to Reverse Course and Return Capital to Shareholders

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Forte Biosciences large shareholders make demands for company's future

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

BML Capital Management Sends an Email to Chairman & CEO of Forte Biosciences

Forte Biosciences, Inc. Appoints Stephen K. Doberstein to its Board

Forte Biosciences, Inc., Annual General Meeting, Jun 01, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

High number of new and inexperienced directors

President recently sold US$4.3m worth of stock

Price target increased to US$103

Director Thomas Darcy has left the company

Forte Biosciences files for $300M mixed shelf offering

Forecast to breakeven in 2025

Forte Biosciences, Inc. Expects to Report the Topline Results from That Trial in the Third Quarter of 2021

Forte Biosciences, Inc. to Report Q4, 2020 Results on Mar 24, 2021

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

New 90-day low: US$30.76

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 2000 Dynamic Index

New 90-day low: US$33.73

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Forte Biosciences readies equity offering

Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis

Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults with Atopic Dermatitis

New 90-day high: US$50.69

Forte Biosciences, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell Small Cap Completeness Index

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 3000 Index

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 2500 Growth Index

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti